ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors

Grant

Date/time Interval

  • June 28, 2017 - June 27, 2020

    • Awarded By

    Total Award Amount

  • 6500.00

    • Direct Costs

  • 5000.00

    • Sponsor Award Id